Eva-maria Nichols PhD

Eva was appointed Head of Complement at GSK's Chemokine, Cytokine and Complement Discovery Performance Unit in 2016, . The group's focus is pre-clinical target/disease validation in complement and development of novel functional assays.

Eva joined GSK's C3 DPU back in 2014, working on the complement-focused early discovery pipeline. Eva completed her postgraduate and postdoctoral research at Newcastle University, UK. Eva’s research involved the generation and testing of recombinant Factor H molecules (“mini-FH”) and scFv fragments for drug-targeting to the glomerular basement membrane.